Relmada Therapeutics, Inc. RLMD Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$19.05M-8.5% | -$19.87M-6.5% | -$10.09M+53.6% | -$9.87M+44.5% | -$17.56M+19.6% | ||
| $956.19K-73.2% | $2.37M-64.7% | $3.61M-54.6% | $4.35M-39.6% | $3.57M-56.9% | ||
| $1.76M+162% | —— | —— | —— | -$2.87M-270% | ||
| -$1.56M+28.9% | —— | -$36.14K— | -$193.78K+89.3% | -$2.19M-44.7% | ||
| $402.43K+239% | —— | —— | —— | -$290.05K+33.0% | ||
| -$540.1K-447% | $186.05K— | $70.28K-74.8% | -$13.8K+69.7% | $155.73K+207% | ||
| -$15.07M+16.6% | -$14.6M-65.9% | -$6.72M+59.6% | -$6.4M+51.7% | -$18.07M-38.6% | ||
| $149.52M+30,544% | $82.79M+12,546% | $233.93K-92.5% | $321.46K-75.3% | $487.92K-93.0% | ||
| $14.29M-9.8% | $5.86M-51.2% | $6.99M-63.7% | $7M-54.3% | $15.85M-7.2% | ||
| $8.09M-32.3% | $8.07M-26.6% | $4.04M-63.8% | $2.82M-73.7% | $11.95M-10.2% | ||
| -$135.23M-980% | -$76.93M-778% | $6.75M-58.2% | $6.68M-52.3% | $15.36M+52.7% | ||
| $3.36M— | —— | —— | —— | —— | ||
| $160M+583% | $23.41M+6,378% | $23.41M+6,578% | $23.41M— | $23.41M+9,387% | ||
| $156.57M— | $93.64M+54,387% | —— | —— | —— | ||
| $6.28M+332% | —— | —— | —— | -$2.71M+1.8% | ||
| $956.2K-73.2% | $3.28M-51.3% | $3.61M-54.6% | $4.35M-39.6% | $3.57M-56.9% | ||
| $402.43K+239% | —— | —— | —— | -$290.05K+33.0% | ||
| —— | —— | —— | —— | $905.23K— | ||
| -$9.87K-116% | -$107.92K-364% | -$81.44K-155% | $47.2K-64.5% | $62.95K+18.5% | ||
| -$9.87K-116% | —— | —— | —— | $62.95K— | ||
| $2.68M+88,039% | —— | —— | $24.61K+2,104% | $3.04K+172% | ||
| -$540.1K-447% | —— | —— | —— | $155.73K— | ||
| $149.52M+30,544% | $82.79M+12,546% | $233.93K-92.5% | $321.46K-75.3% | $487.92K-93.0% | ||
| $14.29M-9.8% | $5.86M-51.2% | $6.99M-63.7% | $7M-54.3% | $15.85M-7.2% | ||
| $65.65K+260% | $18.26K-89.4% | $18.26K-79.6% | $18.26K— | $18.26K-27.0% | ||
| 2.1M— | —— | —— | —— | —— | ||
| —— | 0%— | —— | —— | —— | ||
| —— | -2%— | —— | —— | —— | ||
| $11.37M+81.5% | $12.26M+51.8% | $6.29M-47.0% | $7.4M-8.6% | $6.27M-35.3% | ||
| $959.76K+118% | $387.23K-40.8% | $247.01K-71.2% | $321.46K-66.6% | $440.29K-58.3% | ||
| $409.8K-37.8% | $465.35K+11.2% | $235.85K-81.6% | $354.86K-66.2% | $658.97K-43.2% | ||
| —— | —— | —— | —— | 10%— | ||
| —— | —— | —— | —— | $3.5M+7,678% | ||
| —— | —— | —— | —— | 10%— | ||
| —— | $1.38-55.5% | —— | —— | —— | ||
| —— | 0%— | —— | —— | 0%— | ||
| -2.1M— | —— | —— | —— | —— | ||
| -$65.65K— | —— | —— | —— | —— | ||
| -$540.1K-447% | $186.05K— | $70.28K-74.8% | -$13.8K+69.7% | $155.73K+207% | ||
| 4.2M— | 5.3M— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Relmada Therapeutics, Inc. generate?
- Relmada Therapeutics, Inc. (RLMD) generated -$42.8M in operating cash flow over the trailing twelve months.
- What is Relmada Therapeutics, Inc.'s free cash flow?
- After $182.1M of capital expenditures, Relmada Therapeutics, Inc.'s free cash flow was -$209.9M over the trailing twelve months, down 116.5% year over year.
- Where does Relmada Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Relmada Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.